Axonal protection by combination of ripasudil and brimonidine with upregulation of p-AMPK in TNF-induced optic nerve degeneration

• Published in: International ophthalmology 2024-04, Vol.44 (1), p.173-173, Article 173
• Main Authors: Otsubo, Mizuki, Sase, Kana, Tsukahara, Chihiro, Fujita, Naoki, Arizono, Ibuki, Tokuda, Naoto, Kitaoka, Yasushi
• Format: Article
• Language: English
• Subjects: Adrenergic receptors; AMP-Activated Protein Kinases; Axons; Brimonidine Tartrate; Degeneration; Humans; Isoquinolines; Medicine; Medicine & Public Health; Nerve Degeneration; Nerves; Neuroprotection; Ophthalmology; Optic Atrophy; Optic nerve; Original Paper; Sulfonamides; Up-Regulation
• ISSN: 1573-2630; 0165-5701; 1573-2630
• DOI: 10.1007/s10792-024-03095-9

Purpose The ROCK inhibitor ripasudil hydrochloride hydrate was shown to have axonal protective effects in TNF-induced optic nerve degeneration. The α2-adrenoreceptor agonist brimonidine was also shown to exert axonal protection. The current study aimed to elucidate whether additive axonal protection was achieved by the simultaneous injection of ripasudil and brimonidine and examine the association with AMPK activation. Methods Intravitreal administration was performed in the following groups: PBS, TNF, or TNF with ripasudil, with brimonidine, or with a combination of ripasudil and brimonidine. Axon numbers were counted to evaluate the effects against axon loss. Immunoblot analysis was performed to examine phosphorylated AMPK expression in optic nerves, and immunohistochemical analysis was performed to evaluate the expression levels of p-AMPK and neurofilament in the optic nerve. Results Both ripasudil alone or brimonidine alone resulted in significant neuroprotection against TNF-induced axon loss. The combination of ripasudil and brimonidine showed additive protective effects. Combined ripasudil and brimonidine plus TNF significantly upregulated p-AMPK levels in the optic nerve compared with the TNF groups. Immunohistochemical analysis revealed that p-AMPK is present in axons and enhanced by combination therapy. Conclusion The combination of ripasudil and brimonidine may have additive protective effects compared with single-agent treatment alone. These protective effects may be at least partially associated with AMPK activation.